Inside 'LGL San Diego,' the Bio Hub Set to Open in Songdo [Bio USA]
‘Korean LGL’ by Eli Lilly and Samsung Biologics to Open in Songdo Next July
San Diego Site Offers Free High-End Equipment and Big Pharma Expertise
Targeting Early to Mid-Stage Biotechs (Up to Series B); Resident Recruitment to Begin in Q4 This Y
On the 25th (local time), at the Alexandria Square Megacampus in San Diego, California, USA, the Lilly Gateway Labs (LGL) San Diego site is located in one corner of this area densely populated by biotech companies. The two-story building, with a floor area of about 7,400 square meters, greets visitors on the first floor with its high ceilings and clean white walls. Beyond the glass walls, employees of resident companies could be seen focusing on their work while looking at monitors. Tenant companies are assigned modules that combine office and laboratory space, and in the shared areas, expensive equipment such as plate readers, sequencers, and flow cytometers is provided free of charge. Research infrastructure, including microscope imaging equipment and autoclaves (high-pressure steam sterilizers), is also available, and discounts are offered when using major nearby bio service providers. If needed, adjacent modules can be combined to expand the space.
A view of Eli Lilly's open innovation space, Lilly Gateway Labs (LGL) San Diego site, located in San Diego, California, USA. Photo by Joint Press Team
View original imageThis open innovation hub operated by Eli Lilly will join forces with Samsung Biologics and open its doors in Songdo, Incheon in July next year. During a visit to the San Diego site ahead of the launch of the Korean version of LGL, Verena Stocker, Executive Vice President of LGL Europe, personally explained LGL’s operational philosophy and plans for entering Korea. LGL is an open innovation program launched by Eli Lilly in 2019, and together with Lilly Ventures, Lilly Explore R&D, and Lilly TuneLab, it constitutes the external innovation platform 'Catalyze360.' It provides early-stage biotech companies with integrated access to capital, space, and R&D capabilities so they can progress from research to development. Currently, there are sites in San Francisco (2), Boston, San Diego, and Philadelphia in the United States, as well as Beijing and Shanghai in China. With the addition of Incheon, the total will increase to eight sites. The community includes more than 400 participating companies and members, and there have been over 200 opportunities for exchanges and collaboration with Lilly scientists. Since its inception, tenant companies have collectively raised over $3 billion (approximately 4.4 trillion won) in investment, and more than 150 new therapeutic assets are being developed.
Stocker highlighted LGL’s differentiating factors, stating, "It all started when Lilly realized they were missing opportunities to connect with early-stage, preclinical companies." She explained, "We provide four things to residents: access to capital, research space, scientific expertise, and the use of data models." She further emphasized, "The core principle for partner selection is scientific quality, and for every company joining Catalyze360, we create a unique support plan tailored to their needs." She added that Lilly actively welcomes companies in so-called 'white space'—new therapeutic areas where the company has no existing pipeline.
A panoramic view of Lilly Gateway Labs (LGL) San Diego site, Eli Lilly's open innovation space located in San Diego, California, USA. Photo by Joint Press Team
View original imageStocker also explained why Korea was chosen as a base. She said, "The number of papers published in Korea is very high, the number of biotech companies is rapidly increasing, and the majority are at the preclinical stage," adding, "Strong support from the Korean government for the life sciences sector was also a key factor." She went on to say, "Combining Lilly’s expertise with Samsung Biologics’ capabilities creates a very powerful collaboration model."
LGL's Korean hub will be located within the 'C-Lab Outside' open innovation center currently under construction by Samsung Biologics at the Second Bio Campus in Songdo International City, Incheon. The site consists of five above-ground floors with a total floor area of approximately 12,000 square meters (about 3,500 pyeong) and is scheduled for completion in July next year. Up to 30 biotech companies can move in. The hub will operate as an open innovation center combining Lilly’s scientific and therapeutic expertise with Samsung Biologics’ world-class manufacturing capabilities and CDMO network. This will be the first time a global pharmaceutical company’s open innovation program enters Korea through cooperation with a local firm, and it will be LGL’s second location outside the US after China. Eligible tenants are early- to mid-stage biotechs at Series B or earlier, conducting research in Lilly’s core therapeutic areas, adjacent fields, or new research opportunity areas, excluding companies that have already established partnerships with global big pharma. Recruitment of resident companies is scheduled to begin in the fourth quarter of this year, and the residency period will be two years by default, extendable up to four years. According to LGL, "We do not limit applicants by specific modality or therapeutic area. We prioritize collaboration-oriented teams with scientific potential and top-tier talent."
Overall operations, including the selection and nurturing of tenant companies, will be jointly managed by both companies. Sangmyung Lee, Executive Director in charge of CDO development at Samsung Biologics, said, "Lilly and Samsung will jointly select tenant companies. While Lilly will take the lead in running the program, facility management and general operational decisions will be made together," adding, "All decisions are made jointly." Lee explained, "It is very difficult to be accepted into a big pharma open innovation program, but if you do, it can serve as a strong validation of value."
In addition to its collaboration with LGL, Samsung Biologics is also operating an independent support system for the K-bio ecosystem. Lee stated, "We will establish the K-bio ecosystem based on three pillars: equity investment through the Samsung Life Science Fund, support through the industry promotion fund in the form of cash and research facilities, and connections to the LGL network and educational programs."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.